Cyteir Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cyteir Therapeutics's earnings have been declining at an average annual rate of -21.6%, while the Biotechs industry saw earnings growing at 15.3% annually.
Key information
-21.6%
Earnings growth rate
80.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -26.6% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Is Cyteir Therapeutics (NASDAQ:CYT) In A Good Position To Deliver On Growth Plans?
Oct 25Cyteir Therapeutics GAAP EPS of -$0.34
Aug 08Cyteir Therapeutics (NASDAQ:CYT) Is In A Good Position To Deliver On Growth Plans
Jul 21Here's Why We're Not Too Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Situation
Apr 21Companies Like Cyteir Therapeutics (NASDAQ:CYT) Are In A Position To Invest In Growth
Jan 06We're Not Very Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Rate
Sep 21Cyteir Therapeutics closes lower on first day of trading
Jun 18Revenue & Expenses Breakdown
How Cyteir Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 0 | -33 | 12 | 22 |
30 Jun 23 | 0 | -41 | 13 | 27 |
31 Mar 23 | 0 | -44 | 14 | 31 |
31 Dec 22 | 0 | -46 | 15 | 34 |
30 Sep 22 | 0 | -49 | 15 | 35 |
30 Jun 22 | 0 | -50 | 15 | 35 |
31 Mar 22 | 0 | -49 | 14 | 35 |
31 Dec 21 | 0 | -42 | 11 | 31 |
30 Sep 21 | 0 | -36 | 9 | 39 |
30 Jun 21 | 0 | -29 | 6 | 31 |
31 Mar 21 | 0 | -22 | 5 | 22 |
31 Dec 20 | 0 | -21 | 4 | 17 |
31 Dec 19 | 0 | -15 | 3 | 0 |
Quality Earnings: CYTT is currently unprofitable.
Growing Profit Margin: CYTT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYTT is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.
Accelerating Growth: Unable to compare CYTT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYTT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CYTT has a negative Return on Equity (-26.57%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/03/19 07:36 |
End of Day Share Price | 2024/03/19 00:00 |
Earnings | 2023/09/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyteir Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tazeen Ahmad | BofA Global Research |
Anupam Rama | J.P. Morgan |
Jeff Hung | Morgan Stanley |